We are live on
!
Find out more
Balyasny Asset Management Portfolio holdings
AUM
$77.1B
1-Year Est. Return
42.89%
This Fund
S&P 500
This Quarter
Est. Return
+4.63%
1 Year Est. Return
+42.89%
3 Year Est. Return
+126.29%
5 Year Est. Return
+172.74%
10 Year Est. Return
+763.65%
AUM
$77.1B
AUM Growth
-$1.68B
(-2.1%)
Cap. Flow
-$2.68B
Cap. Flow
% of AUM
-3.48%
Top 10 Holdings %
Top 10 Hldgs %
16.75%
Holding
3,716
New
704
Increased
979
Reduced
1,056
Closed
911
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$626M |
| 2 |
Warner Bros
WBD
|
+$447M |
| 3 |
Apple
AAPL
|
+$436M |
| 4 |
RTX Corp
RTX
|
+$434M |
| 5 |
Constellation Brands
STZ
|
+$320M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$1.13B |
| 2 |
Microsoft
MSFT
|
+$502M |
| 3 |
RNAM
Avidity Biosciences
RNAM
|
+$436M |
| 4 |
EXAS
Exact Sciences
EXAS
|
+$415M |
| 5 |
Electronic Arts
EA
|
+$388M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 9.75% |
| 2 | Industrials | 9.36% |
| 3 | Consumer Discretionary | 8.52% |
| 4 | Healthcare | 7.75% |
| 5 | Financials | 7.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
576
Kiniksa Pharmaceuticals
KNSA
$5.8B
| $24.1M | 0.03% |
+499,792
| New | +$22.1M |
|
|
XLKI
577
PUT
State Street Technology Select Sector SPDR Premium Income ETF
XLKI
$11.5M
| $23.9M | 0.03% |
+180,000
| New | +$4.5M |
|
578
PUT
Lowe's Companies
LOW
$117B
| $23.9M | 0.03% |
101,200
+48,500
| +92% | +$12.6M |
|
579
JPMorgan Chase
JPM
$935B
| $23.9M | 0.03% |
81,225
-543,782
| -87% | -$165M |
|
|
ABVX
580
Abivax
ABVX
$10.9B
| $23.8M | 0.03% |
213,689
-144,633
| -40% | -$17.1M |
|
581
CALL
State Street SPDR S&P Oil & Gas Exploration & Production ETF
XOP
$3.65B
| $23.6M | 0.03% |
130,000
-24,500
| -16% | -$3.69M |
|
582
PUT
Starbucks
SBUX
$120B
| $23.6M | 0.03% |
263,700
+239,900
| +1,008% | +$22.7M |
|
583
SL Green Realty
SLG
$3.76B
| $23.5M | 0.03% |
635,265
+557,939
| +722% | +$23.2M |
|
584
Zillow
Z
$7.79B
| $23.4M | 0.03% |
564,453
+509,303
| +923% | +$27.1M |
|
585
Remitly
RELY
$4.79B
| $23.3M | 0.03% |
1,487,150
+953,151
| +178% | +$14.1M |
|
|
BIOA
586
BioAge Labs
BIOA
$402M
| $23.2M | 0.03% |
+1,327,545
| New | +$25.6M |
|
|
SCHW
587
CALL
Charles Schwab
SCHW
$183B
| $23.2M | 0.03% |
246,700
-31,400
| -11% | -$3.08M |
|
588
CALL
Invesco S&P 500 Equal Weight ETF
RSP
$97B
| $23.2M | 0.03% |
120,700
+99,400
| +467% | +$19.7M |
|
589
Cleveland-Cliffs
CLF
$6.57B
| $23.1M | 0.03% |
2,733,399
-6,643,924
| -71% | -$76M |
|
|
DEA
590
Easterly Government Properties
DEA
$1.13B
| $23M | 0.03% |
1,071,552
+149,894
| +16% | +$3.42M |
|
591
iRhythm Holdings
IRTC
$3.85B
| $22.9M | 0.03% |
194,429
+27,155
| +16% | +$3.92M |
|
592
Atour Lifestyle Holdings
ATAT
$4.67B
| $22.9M | 0.03% |
+621,508
| New | +$23.4M |
|
593
Ocular Therapeutix
OCUL
$1.79B
| $22.8M | 0.03% |
2,692,622
+1,929,063
| +253% | +$18.4M |
|
|
LBRX
594
LB Pharmaceuticals
LBRX
$1.15B
| $22.8M | 0.03% |
923,694
+26,888
| +3% | +$620K |
|
|
THR
595
DELISTED
Thermon Group Holdings
THR
| $22.7M | 0.03% |
450,549
+435,969
| +2,990% | +$20.3M |
|
596
Aecom
ACM
$9.3B
| $22.7M | 0.03% |
+267,610
| New | +$25.4M |
|
|
ECHO
597
CALL
EchoStar
ECHO
$24.4B
| $22.7M | 0.03% |
193,800
+113,800
| +142% | +$13.1M |
|
598
Simmons First National
SFNC
$3.41B
| $22.6M | 0.03% |
1,164,479
+842,590
| +262% | +$16.8M |
|
599
IAMGOLD
IAG
$8.2B
| $22.5M | 0.03% |
1,195,082
+1,159,359
| +3,245% | +$23M |
|
600
CALL
State Street Health Care Select Sector SPDR ETF
XLV
$41.9B
| $22.5M | 0.03% |
153,400
+14,100
| +10% | +$2.17M |
|
Similar funds
CBU
BC
Balyasny Asset Management's Q1 2026 Portfolio in Review
As of Q1 2026, Balyasny Asset Management held 3,716 positions worth $77.1B, down 2.1% from $78.8B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Balyasny Asset Management withdrew a net $2.68B in Q1 2026, closing 911 positions and reducing 1,056 holdings. Its most notable exit was iShares Core S&P 500 ETF, an estimated $1.13B position sold in full.
By sector, the portfolio is most concentrated in Technology at 9.7% of assets, down from 12% a quarter earlier, followed by Industrials and Consumer Discretionary.
Against the trend, Balyasny Asset Management opened a new position in Silicon Laboratories worth $257M.
- Balyasny Asset Management's largest Q1 2026 buy was Silicon Laboratories: 1,233,893 shares worth $257M.
- Balyasny Asset Management added most to Meta Platforms (Facebook) in Q1 2026, an estimated $626M increase.
- Balyasny Asset Management's biggest Q1 2026 reduction was Microsoft, cutting an estimated $502M.
- Balyasny Asset Management fully exited iShares Core S&P 500 ETF in Q1 2026, selling an estimated $1.13B.
- Balyasny Asset Management's ten largest holdings make up 17% of its $77.1B portfolio in Q1 2026.
- Balyasny Asset Management opened 704 new positions and closed 911 in Q1 2026.
- Balyasny Asset Management's portfolio value fell 2.1% quarter-over-quarter to $77.1B.
Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.